These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 38374735)

  • 1. A Pragmatic, Investigator-Driven Process for Disclosure of Amyloid PET Scan Results to ADNI-4 Research Participants.
    Erickson CM; Karlawish J; Grill JD; Harkins K; Landau SM; Rivera-Mindt MG; Okonkwo O; Petersen RC; Aisen PS; Weiner MW; Largent EA
    J Prev Alzheimers Dis; 2024; 11(2):294-302. PubMed ID: 38374735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.
    Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Liu E; Morris JC; Petersen RC; Saykin AJ; Schmidt ME; Shaw L; Shen L; Siuciak JA; Soares H; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2013 Sep; 9(5):e111-94. PubMed ID: 23932184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using AD biomarker research results for clinical care: a survey of ADNI investigators.
    Shulman MB; Harkins K; Green RC; Karlawish J
    Neurology; 2013 Sep; 81(13):1114-21. PubMed ID: 23966249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.
    Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Liu E; Morris JC; Petersen RC; Saykin AJ; Schmidt ME; Shaw L; Siuciak JA; Soares H; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2012 Feb; 8(1 Suppl):S1-68. PubMed ID: 22047634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitively unimpaired adults' reactions to disclosure of amyloid PET scan results.
    Largent EA; Harkins K; van Dyck CH; Hachey S; Sankar P; Karlawish J
    PLoS One; 2020; 15(2):e0229137. PubMed ID: 32053667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Family members' perspectives on learning cognitively unimpaired older adults' amyloid-β PET scan results.
    Largent EA; Abera M; Harkins K; Feldman SJ; Uhlmann WR; Roberts JS; Karlawish J;
    J Am Geriatr Soc; 2021 Nov; 69(11):3203-3211. PubMed ID: 34252201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid Levels.
    Steward A; Biel D; Dewenter A; Roemer S; Wagner F; Dehsarvi A; Rathore S; Otero Svaldi D; Higgins I; Brendel M; Dichgans M; Shcherbinin S; Ewers M; Franzmeier N
    JAMA Neurol; 2023 Dec; 80(12):1295-1306. PubMed ID: 37930695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Communicating Alzheimer's biomarker results to cognitively unimpaired research participants: Satisfaction, utility, and impact on research attitudes.
    Erickson CM; Ketchum FB; Basche KE; Chin NA; Eveler ML; Clark LR
    Alzheimers Dement (N Y); 2024; 10(2):e12483. PubMed ID: 38882702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amnestic MCI patients' experiences after disclosure of their amyloid PET result in a research context.
    Vanderschaeghe G; Schaeverbeke J; Bruffaerts R; Vandenberghe R; Dierickx K
    Alzheimers Res Ther; 2017 Dec; 9(1):92. PubMed ID: 29197423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease.
    Young CB; Winer JR; Younes K; Cody KA; Betthauser TJ; Johnson SC; Schultz A; Sperling RA; Greicius MD; Cobos I; Poston KL; Mormino EC;
    JAMA Neurol; 2022 Jun; 79(6):592-603. PubMed ID: 35435938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "And Does That Necessarily Mean Absolutely Alzheimer's?" An Analysis of Questions Raised Following Amyloid PET Results Disclosure.
    Kim JE; Tamres LK; Orbell SL; Cheng RZ; Klunk WE; Aizenstein HJ; Butters MA; McDade E; Lingler JH
    Am J Geriatr Psychiatry; 2024 Jan; 32(1):45-54. PubMed ID: 37634955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core.
    Jagust WJ; Bandy D; Chen K; Foster NL; Landau SM; Mathis CA; Price JC; Reiman EM; Skovronsky D; Koeppe RA;
    Alzheimers Dement; 2010 May; 6(3):221-9. PubMed ID: 20451870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography.
    Meyer PF; Pichet Binette A; Gonneaud J; Breitner JCS; Villeneuve S
    JAMA Neurol; 2020 Apr; 77(4):508-516. PubMed ID: 31961372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerability.
    Lim YY; Maruff P; Getter C; Snyder PJ
    Alzheimers Dement; 2016 Apr; 12(4):454-8. PubMed ID: 26750717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials.
    Iwatsubo T; Iwata A; Suzuki K; Ihara R; Arai H; Ishii K; Senda M; Ito K; Ikeuchi T; Kuwano R; Matsuda H; ; Sun CK; Beckett LA; Petersen RC; Weiner MW; Aisen PS; Donohue MC;
    Alzheimers Dement; 2018 Aug; 14(8):1077-1087. PubMed ID: 29753531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterizing Amyloid-Positive Individuals With Normal Tau PET Levels After 5 Years: An ADNI Study.
    Josephs KA; Weigand SD; Whitwell JL
    Neurology; 2022 May; 98(22):e2282-e2292. PubMed ID: 35314506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
    Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stakeholders' Views on Early Diagnosis for Alzheimer's Disease, Clinical Trial Participation and Amyloid PET Disclosure: A Focus Group Study.
    Vanderschaeghe G; Vandenberghe R; Dierickx K
    J Bioeth Inq; 2019 Mar; 16(1):45-59. PubMed ID: 30868358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment.
    Grill JD; Raman R; Ernstrom K; Sultzer DL; Burns JM; Donohue MC; Johnson KA; Aisen PS; Sperling RA; Karlawish J;
    JAMA Neurol; 2020 Dec; 77(12):1504-1513. PubMed ID: 32777010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography.
    Therriault J; Vermeiren M; Servaes S; Tissot C; Ashton NJ; Benedet AL; Karikari TK; Lantero-Rodriguez J; Brum WS; Lussier FZ; Bezgin G; Stevenson J; Rahmouni N; Kunach P; Wang YT; Fernandez-Arias J; Socualaya KQ; Macedo AC; Ferrari-Souza JP; Ferreira PCL; Bellaver B; Leffa DT; Zimmer ER; Vitali P; Soucy JP; Triana-Baltzer G; Kolb HC; Pascoal TA; Saha-Chaudhuri P; Gauthier S; Zetterberg H; Blennow K; Rosa-Neto P
    JAMA Neurol; 2023 Feb; 80(2):188-199. PubMed ID: 36508198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.